A promising breakthrough in the fight against cancer emerges from Russia. The cancer vaccine developed by the Gamaleya Center ...

Former 'Real Housewives of Beverly Hills' star Teddi Mellencamp has been candid about her journey since being diagnosed with ...

The first patient was enrolled in a phase 3 trial for patients with non-metastatic uveal melanoma to either receive Kimmtrak ...

The FDA has approved cosibelimab (marketed under the brand name Unloxcyt), a new drug for adults with advanced cutaneous squamous cell carcinoma (CSCC), a type of skin cancer.

Checkpoint Therapeutics' Unloxcyt wins FDA approval for advanced cSCC, marking the company's entry into the U.S. market, valued over $1 billion annually.

Familial malignant melanoma refers to families in which two or more first ... People with weakened immune systems because of ...

UNLOXCYT (cosibelimab-ipdl) is indicated for the treatment of adults with metastatic cutaneous squamous cell carcinoma (“cSCC”) or locally advanced cSCC who are not candidates for curative surgery or ...

Unloxcyt was approved by the FDA as a new treatment for patients with locally ... for patients with locally advanced or ...

IMM-1-104 has the potential to benefit melanoma patients who have progressed on or are intolerant to immune checkpoint inhibitors -- IMM-1-104 ...

A professor at the University of Illinois is pioneering cancer research that could curb tumor growth. Erik Nelson is an ...

This page includes links to articles highlighting the top skin cancer research published on Cancer Therapy Advisor in 2024.

ATOM is the only active Phase 3 trial for adjuvant treatment of uveal melanoma The trial will assess whether adjuvant treatment with tebentafusp can decrease the risk of relapse, compared to ...